Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results Nov 06, 2008 Nektar Therapeutics to Webcast R&D Day on November 12th Oct 27, 2008 Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium Oct 24, 2008 Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets Oct 23, 2008 Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference Oct 23, 2008 Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder Oct 21, 2008 Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City Oct 07, 2008 Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City Sep 16, 2008 Nektar Therapeutics Announces Second Quarter 2008 Results Aug 06, 2008 Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer Aug 06, 2008 Pagination First page « first Previous page ‹ previous … Page 40 Page 41 Page 42 Page 43 Current page 44 Page 45 Page 46 Page 47 Page 48 … Next page next › Last page last »